Dennis Ruff

439 total citations
19 papers, 366 citations indexed

About

Dennis Ruff is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Physiology. According to data from OpenAlex, Dennis Ruff has authored 19 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 7 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Physiology. Recurrent topics in Dennis Ruff's work include Nitric Oxide and Endothelin Effects (5 papers), Blood Pressure and Hypertension Studies (4 papers) and Hormonal Regulation and Hypertension (4 papers). Dennis Ruff is often cited by papers focused on Nitric Oxide and Endothelin Effects (5 papers), Blood Pressure and Hypertension Studies (4 papers) and Hormonal Regulation and Hypertension (4 papers). Dennis Ruff collaborates with scholars based in United States, Switzerland and Canada. Dennis Ruff's co-authors include Kenny Frazier, Ike Ogbaa, Anne Turnage, Phillip Banks, Arthur Sands, Joel Freiman, Brian Zambrowicz, David R. Powell, David Crockford and Yuxin Zhang and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Diabetes.

In The Last Decade

Dennis Ruff

18 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dennis Ruff United States 10 163 111 102 100 76 19 366
Sibel Özyazgan Türkiye 11 80 0.5× 77 0.7× 52 0.5× 59 0.6× 49 0.6× 33 344
A J Scheen Belgium 9 166 1.0× 107 1.0× 79 0.8× 44 0.4× 79 1.0× 23 368
Kazuyasu Maruyama Japan 12 115 0.7× 230 2.1× 60 0.6× 102 1.0× 26 0.3× 27 532
Liwei Ren China 14 168 1.0× 282 2.5× 113 1.1× 196 2.0× 41 0.5× 30 574
Hiroyasu Hirose Japan 10 91 0.6× 132 1.2× 106 1.0× 52 0.5× 53 0.7× 16 505
Aya Shiraki Japan 8 215 1.3× 168 1.5× 99 1.0× 83 0.8× 38 0.5× 16 513
Christopher Doe United States 14 72 0.4× 199 1.8× 139 1.4× 220 2.2× 113 1.5× 21 579
Yoshiharu Horie Japan 11 238 1.5× 105 0.9× 76 0.7× 56 0.6× 51 0.7× 18 423
Elena Zinßius Germany 6 279 1.7× 212 1.9× 135 1.3× 108 1.1× 50 0.7× 7 596

Countries citing papers authored by Dennis Ruff

Since Specialization
Citations

This map shows the geographic impact of Dennis Ruff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Ruff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Ruff more than expected).

Fields of papers citing papers by Dennis Ruff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis Ruff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Ruff. The network helps show where Dennis Ruff may publish in the future.

Co-authorship network of co-authors of Dennis Ruff

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis Ruff. A scholar is included among the top collaborators of Dennis Ruff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis Ruff. Dennis Ruff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
James, Ian E., et al.. (2021). Two‐Part Phase 1 Multiple‐Ascending‐Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults. Clinical Pharmacology in Drug Development. 11(1). 51–62. 5 indexed citations
3.
James, Ian E., et al.. (2019). A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid Receptor. Clinical Pharmacology in Drug Development. 9(2). 256–266. 20 indexed citations
4.
Hanrahan, John P., James Wakefield, Phebe Wilson, et al.. (2018). Rapid Dose Escalation Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension. Diabetes. 67(Supplement_1). 1 indexed citations
5.
Hanrahan, John P., James Wakefield, Phebe Wilson, et al.. (2018). A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects. Clinical Pharmacology in Drug Development. 8(5). 564–575. 25 indexed citations
6.
Mittleman, Robert S., Phebe Wilson, Marina Mihova, et al.. (2017). Multiple-Ascending-Dose Study of the Soluble Guanylate Cyclase Stimulator, IW-1701, in Healthy Subjects. Blood. 130. 3533–3533. 5 indexed citations
7.
Hanrahan, John P., James Wakefield, Phebe Wilson, et al.. (2017). Abstract P493: Multiple-ascending-dose Study of IW-1973, a Soluble Guanylate Cyclase Stimulator. Hypertension. 70(suppl_1). 1 indexed citations
8.
Hanrahan, John P., Albert T. Profy, Bernard J. Lavins, et al.. (2016). FIRST-IN-HUMAN SINGLE-ASCENDING-DOSE STUDY OF IW-1973, A NEW SOLUBLE GUANYLATE CYCLASE STIMULATOR. Journal of the American College of Cardiology. 67(13). 1284–1284. 3 indexed citations
9.
Elahi, Dariush, Dennis Ruff, Olga D. Carlson, et al.. (2015). Does GLP-1 suppress its own basal secretion?. Endocrine Research. 41(1). 16–20. 9 indexed citations
10.
Zambrowicz, Brian, Zhi‐Ming Ding, Ike Ogbaa, et al.. (2013). Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics. 35(3). 273–285.e7. 65 indexed citations
11.
12.
Wang, Ping, et al.. (2013). Absence of an effect of T89 on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. The Journal of Clinical Pharmacology. 54(2). 234–239. 10 indexed citations
13.
Ruff, Dennis, et al.. (2010). A randomized, placebo‐controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Annals of the New York Academy of Sciences. 1194(1). 223–229. 36 indexed citations
14.
Scott, Graham, Christiane Rordorf, Christine Reynolds, et al.. (2004). Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid. Clinical Pharmacokinetics. 43(7). 467–478. 55 indexed citations
15.
Black, Henry R., W.J. Elliott, Michael A. Weber, et al.. (2001). One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension. Hypertension. 38(5). 1118–1123. 22 indexed citations
16.
DeQuattro, Vincent, et al.. (1999). Effective dose range of Candesartan cilexetil for systemic hypertension. The American Journal of Cardiology. 83(2). 272–275. 12 indexed citations
17.
Neutel, Joel M., Vardaman M. Buckalew, Steven G. Chrysant, et al.. (1999). Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study. American Heart Journal. 137(1). 118–125. 9 indexed citations
18.
19.
Ruff, Dennis, et al.. (1985). Pseudomembranous Colitis Following Low Dose Trimethoprim-Sulfamethoxazole. The Journal of Urology. 134(6). 1218–1219. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sibel Özyazgan Breakdown of academic impact, for papers by A J Scheen Breakdown of academic impact, for papers by Kazuyasu Maruyama Breakdown of academic impact, for papers by Liwei Ren Breakdown of academic impact, for papers by Hiroyasu Hirose Breakdown of academic impact, for papers by Aya Shiraki Breakdown of academic impact, for papers by Christopher Doe Breakdown of academic impact, for papers by Yoshiharu Horie Breakdown of academic impact, for papers by Elena Zinßius
Rankless by CCL
2026